MetLife said its net income available to MetLife, Inc.’s common shareholders was $1.4 billion in 2023, $5.1 billion in 2022 and $6.7 billion in 2021, and that adjusted earnings available to common shareholders were $5.5 billion, $5.8 billion and $7.9 billion, respectively.

1. 01

   MetLife said its net income available to MetLife, Inc.’s common shareholders was $1.4 billion in 2023, $5.1 billion in 2022 and $6.7 billion in 2021, and that adjusted earnings available to common shareholders were $5.5 billion, $5.8 billion and $7.9 billion, respectively.

2. 02

   The company said net income available to common shareholders decreased $3.7 billion in 2023 from 2022, citing an unfavorable change of $1.6 billion in net investment gains (losses) and an unfavorable change of $2.7 billion in market risk benefit remeasurement (gains) losses as the main items.

3. 03

   The company said adjusted premiums, fees and other revenues decreased $4.2 billion (7%) in 2023 from 2022, and attributed the decline mainly to lower premiums in its RIS segment, driven by a large pension risk transfer transaction in 2022.

4. 04

   The company said its holding company cash and liquid assets were $5.2 billion as of December 31, 2023, above the high end of its $3.0 billion to $4.0 billion holding company cash target. It said it expects to maintain this target in 2024.

Key figures

Fiscal year ended December 31, 2023

Revenue

$66.9B

Net income

$1.6B

EPS

$1.81

Operating cash flow

$13.7B

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.